In patients with CKD, does dual-RAS inhibition compared to mono-RAS inhibition improve clinical efficacy outcomes and reduce adverse effects?
A Cochrane review by Strippoli GFM, et al. (2006) found that dual-RAS inhibition may improve clinical efficacy outcomes and reduce adverse effects in patients with CKD compared to mono-RAS inhibition. This review included randomized controlled trials (RCTs) and studied critical and important harms listed in Table 1.